Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 507-522

  Hirschowitz, B I ^a   Mohnen, J ^a   Shaw, S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; LANSOPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; GASTRECTOMY; GASTRINOMA; HUMAN; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

EID: 0030016836     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.10152000.x     Document Type: Article

References (43)

1. Jensen RT, Gardner JD, Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis, and treatment. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-related Disorders. Armonk, New York: Academic Research Association, 1991: 117-211.
2. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6.
3. Hirschowitz BI. Pathobiology and management of hypergastrinemia and the Zollinger-Ellison syndrome. Yale J Biol Med 1992; 65: 659-76.
4. Metz DC, Benya RV, Fishbeyn VA, et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther 1993; 7: 247-57.
5. Bonfils S, Landor JH, Mignon M, Hervoir P. Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. Ann Surg 1981; 194: 692-7.
6. Pisegna J, Norton JA, Slimak GG, et al. Effect of curative gastrinoma resection on gastric secretory function and anti-secretory drug requirement in Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767-78.
7. Howard TJ, Zinner MJ, Stabile BE, Passaro E, Jr. Gastrinoma excision for cure. A prospective analysis. Ann Surg 1990; 211: 9-14.
8. Hirschowitz BI. Clinical course of nonsurgically treated Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumours of the Pancreas - Recent Advances, Vol. 23 of Frontiers in Gastrointestinal Research series. Basel: S. Karger AG, 1994.
9. Thompson JC, Lewis BG, Wiener I, Townsend CM, Jr. The role of surgery in the Zollinger-Ellison syndrome. Ann Surg 1983; 197: 594-607.
10. Ellison EC, Carey LC, Sparks J, et al. Early surgical treatment of gastrinoma. Am J Med 1987; 82: 17-24.
11. 2-receptors. Nature 1972; 236: 385-90.
12. Hirschowitz BI, Keeling D, Lewin M, et al. Pharmacological aspects of acid secretion. Dig Dis Sci 1995; 40 (Suppl.): 3S-23S.
13. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989; 97: 827-36.
14. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610.
15. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 1988; 94: 294-9.
16. ++K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989; 248: 799-805.
17. Satoh H, Inatomi N, Nagaya H, et al. Anti-secretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989; 248: 806-15.
18. Mignon M, Hochlaf S, Forestier S, et al. Dose response effect of lansoprazole in patients with Zollinger-Ellison syndrome. Gastroenterol Clin Biol 1994; 18: 13-6.
19. Barradell LB, Faulds D, McTavish D, Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50.
20. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 245-56.
21. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993; 7: 41-50.
22. Mignon M, Pospai D, Forestier S, Vatier J, Vallot T. Treatment of patients with Zollinger-Ellison syndrome. Clin Ther 1993; 15 (Suppl. B): 22-31.
23. Hirschowitz BI, Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci 1993; 38: 1874-84.
24. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
25. Hirschowitz BI. Apparent and intrinsic sensitivity to pentagastrin of acid and pepsin secretion in peptic ulcer. Gastroenterology 1984; 86: 843-51.
26. Hirschowitz BI. Pepsin in the pathogenesis of peptic ulceration. In: Halter F, Garner A, Tytgat GNJ, eds. Mechanisms of Peptic Ulcer Healing. Dordrecht: Kluwer Academic, 1990: 183-94.
27. Cadiot G, Lehy T, Ruszniewski P, Bonfils S, Mignon M. Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. Dig Dis Sci 1993; 38: 1307-17.
28. Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99: 943-50.
29. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-9.
30. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
31. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Aliment Pharmacol Ther 1996; 10: 497-506.
32. Solcia E, Bordi C, Creutzfeld W, et al. Histopathological classification of non-antral gastric endocrine growths in man. Digestion 1988; 41: 185-200.
33. Norton JA, Doppman JL, Collen MJ, et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986; 204: 468-78.
34. Stabile B, Passarro E. Benign and malignant gastrinoma. Am J Surg 1985; 149: 144-9.
35. Jensen RT. Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1984; 29: 363-6.
36. McCarthy DM, Hyman PE. Effect of isopropramide on response to oral cimetidine in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1982; 27: 353-7.
37. Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacology and therapeutic efficacy in peptic ulcer disease. Drugs 1978; 15: 93-151.
38. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1496-1508.
39. Gramley WA, Craig J, Hirschowitz BI. Evaluation of low basal acid output (BAO) using maximal acid output (MAO) and 24 hour gastric pH monitoring in patients treated with the proton pump inhibitor (PPI) lansoprazole. Gastroenterology Suppl. 1994; 106: A83 (Abstract).
40. Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-related Disorders. Armonk, New York: Academic Research Association, 1991: 213-46.
41. Vallot T, Mignon M, Mazure R, Bonfils S. Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring. Dig Dis Sci 1983; 28: 577-84.
42. Burget D, Chiverton SG, Hunt R. Is there an optimal degree of acid suppression for healing duodenal ulcers? Gastroenterology 1990; 99: 345-41.
43. Bruley Des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.